Page 10 - Under Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RushNet Inc. Cancellation of Proposed Reverse Split ACCESSWIRE ALPHARETTA, GA / ACCESSWIRE / June 9, 2021 / RushNet, Inc. (OTC PINK:RSHN) ('RushNet') with merger/acquisition target heliosDX, is pleased to announce the official cancelation of the proposed Reverse Split (RS). The company will file with the Colorado Secretary of State to reflect such cancelation. About HeliosDx: heliosDX is a National Independent Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic T...

Link Reservations Inc. (Stock Symbol: LRSV) is a Global Provider of Wellness Products for Pets and People

Die Passstrasse aus den 1930er-Jahren verbindet das Mittelland mit dem Schwarzbubenland. Mit verschiedenen Bauprojekten bügelt der Kanton die Abnützung aus. Im Schwarzbubenland sorgt das jedoch nicht nur für Freude.

RESUMPTION OF TRADING 2020 ANNUAL RESULTS HIGHLIGHTS Achieved contracted sales for the year ended December 31, 2020 (the "Reporting Period") of RMB18,532.2 million with corresponding gross floor area ("GFA") of approximately 1,014,003 sq.m.; Revenue for the Reporting Period was RMB5,768.9 million, of which the revenue from property development was RMB5,016.8 million; Gross profit for the Reporting Period was RMB1,045.5 million; Profit for the year, excluding the one-off loss on disposal of the eight real estate project compan...

Sun Pharma Advanced Research Company (SPARC) skids 2.21% to Rs 170 after the company said that the US drug regulator has ruled against its appeal related to Taclantis, its under-development product for the treatment of breast cancer.The Office of New Drugs (OND) of the U.S. Food and Drug Administration (USFDA) has denied the company's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for Taclantis. Taclantis is a novel formulation of paclitaxel developed with SPARC's proprietary Nanotecton technology. Paclitaxel is one of the most widely used cytotoxic agent...